Lumos Diagnostics Hits Enrollment Milestone in Pediatric Clinical Study of Respiratory Infection Testing Tool; Shares Down 4%

MT Newswires Live

May 14

Lumos Diagnostics Holdings (ASX:LDX) completed the enrollment of 250 patients in the Biomedical Advanced Research and Development Authority (BARDA)-funded pediatric clinical study of the FebriDx rapid point-of-care test for acute respiratory infections, according to a Thursday Australian bourse filling.

This triggered a $670,000 milestone payment under Lumos' agreement with BARDA, bringing the total milestone payments received to date to $2.6 million, the filing said.

The study is evaluating the use of the FebriDx device in children between the ages of two to 12 years to differentiate bacterial from non-bacterial acute respiratory infections, per the filing. It is expected to run for around 12 months.

Lumos Diagnostics Holdings' shares tumbled 4% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2635763820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635763820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635763820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635763820","market":"nz","top_or_hot":-1,"title":"Lumos Diagnostics Hits Enrollment Milestone in Pediatric Clinical Study of Respiratory Infection Testing Tool; Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings (ASX:LDX) completed the enrollment of 250 patients in the Biomedical Advanced Research and Development Authority (BARDA)-funded pediatric clinical study of the FebriDx rapid point-of-care test for acute respiratory infections, according to a Thursday Australian bourse filling.</p><p>This triggered a $670,000 milestone payment under Lumos' agreement with BARDA, bringing the total milestone payments received to date to $2.6 million, the filing said.</p><p>The study is evaluating the use of the FebriDx device in children between the ages of two to 12 years to differentiate bacterial from non-bacterial acute respiratory infections, per the filing. It is expected to run for around 12 months.</p><p><a href=\"https://laohu8.com/S/LDX.AU\">Lumos Diagnostics</a> Holdings' shares tumbled 4% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Diagnostics Hits Enrollment Milestone in Pediatric Clinical Study of Respiratory Infection Testing Tool; Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Diagnostics Hits Enrollment Milestone in Pediatric Clinical Study of Respiratory Infection Testing Tool; Shares Down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-14 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings (ASX:LDX) completed the enrollment of 250 patients in the Biomedical Advanced Research and Development Authority (BARDA)-funded pediatric clinical study of the FebriDx rapid point-of-care test for acute respiratory infections, according to a Thursday Australian bourse filling.</p><p>This triggered a $670,000 milestone payment under Lumos' agreement with BARDA, bringing the total milestone payments received to date to $2.6 million, the filing said.</p><p>The study is evaluating the use of the FebriDx device in children between the ages of two to 12 years to differentiate bacterial from non-bacterial acute respiratory infections, per the filing. It is expected to run for around 12 months.</p><p><a href=\"https://laohu8.com/S/LDX.AU\">Lumos Diagnostics</a> Holdings' shares tumbled 4% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7126","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635763820","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635763820","pubTimestamp":1778722841,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics Holdings  completed the enrollment of 250 patients in the Biomedical Advanced Research and Development Authority -funded pediatric clinical study of the FebriDx rapid point-of-care test for acute respiratory infections, according to a Thursday Australian bourse filling.This triggered a $670,000 milestone payment under Lumos' agreement with BARDA, bringing the total milestone payments received to date to $2.6 million, the filing said.The study is evaluating the use of the FebriDx device in children between the ages of two to 12 years to differentiate bacterial from non-bacterial acute respiratory infections, per the filing. It is expected to run for around 12 months.Lumos Diagnostics Holdings' shares tumbled 4% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7126":"医疗保健用品","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L"},"translate_title":"Lumos Diagnostics在呼吸道感染检测工具的儿科临床研究中达到入组里程碑；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDX.AU":1},"content_text":"Lumos Diagnostics Holdings (ASX:LDX) completed the enrollment of 250 patients in the Biomedical Advanced Research and Development Authority (BARDA)-funded pediatric clinical study of the FebriDx rapid point-of-care test for acute respiratory infections, according to a Thursday Australian bourse filling.This triggered a $670,000 milestone payment under Lumos' agreement with BARDA, bringing the total milestone payments received to date to $2.6 million, the filing said.The study is evaluating the use of the FebriDx device in children between the ages of two to 12 years to differentiate bacterial from non-bacterial acute respiratory infections, per the filing. It is expected to run for around 12 months.Lumos Diagnostics Holdings' shares tumbled 4% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}